When buying a quality company whose stock is falling due to bad news, Terry Smith often buys in three separate tranches. He did this with Fortinet as its growth slowed post-COVID. His rationale is that negative news and earnings warnings often 'come in threes,' and this staggered approach helps manage entry price risk.
Related Insights
Instead of making large initial bets, a more effective strategy is to take small, "junior varsity" positions. Investors then aggressively ramp up their size only when the thesis begins to demonstrably play out, a method described as "high conviction, inflection investing."
In venture capital, the greatest danger isn't investing at high valuations during a boom; it's ceasing to invest during a bust. The psychological pressure to stop when markets are negative is immense, but the best VCs maintain a disciplined, mechanical pace of investment to ensure they are active at the bottom.
The textbook value investing response—buying more as a stock falls—is often impractical. In firms focused on short-term performance, a stock dropping from $70 to $30 after a buy recommendation can get an analyst fired, even if the thesis is ultimately correct. This institutional pressure shortens time horizons.
A powerful market signal is the "quad count," or the forecasted sequence of economic regimes. A progression from Quad 4 (recession fears) to Quad 3 and then to Quads 2 and 1 creates a powerful contrarian setup. This allows investors to buy assets like small caps when recession probabilities are priced at their highest.
Challenging traditional value investing dogma, the speaker advocates for averaging up—buying more of a stock as its price rises. This strategy treats price appreciation as confirmation of a correct thesis, allowing an investor to build a larger position in their best-performing ideas rather than just adding to laggards.
To avoid emotional spending that kills runway, analyze every major decision through three financial scenarios. A 'bear' case (e.g., revenue drops 10%), 'base' case (plan holds), and 'bull' case (revenue grows 10%). This sobering framework forces you to quantify risk and compare alternatives objectively before committing capital.
Anchoring valuation on a company's typical price-to-sales ratio helps identify buying opportunities when margins are temporarily depressed. This avoids the pitfalls of methods like the Magic Formula, which can mistakenly favor companies at their cyclical earnings peaks, leading to underperformance.
One of the few working quantitative models in biotech is to systematically purchase stocks after they have crashed on bad news. This low-batting-average, high-slugging-percentage approach is terrifying but can work by getting favorable odds on a recovery, provided the company has sufficient cash runway to survive.
Applying Ben Graham's "unpopular large caps" principle to well-known companies like Meta is a powerful strategy. When the market punishes a fundamentally strong large cap for temporary concerns, it creates an attractive entry point. Unlike less-followed stocks, US large caps often rebound quickly once the narrative proves to be an overreaction.
Rather than passively holding a stock, the "buy and optimize" strategy involves actively managing its weighting in a portfolio. As a stock becomes more expensive relative to its intrinsic value, the position is trimmed, and when it gets cheaper, it is increased, creating an additional layer of return.
